Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polidocanol + urea is a topical combination used primarily in dermatology for the symptomatic relief of pruritus (itching) and the treatment of dry skin conditions. Polidocanol acts as a local anesthetic and antipruritic agent, though its exact mechanism for itch relief is not fully defined; it may reduce nerve irritation and has mild anesthetic properties. Urea is a keratolytic and humectant that improves skin hydration by increasing water uptake in the stratum corneum, softening hyperkeratotic areas, and enhancing desquamation. The combination leverages both agents' effects to relieve itching while improving skin moisture barrier function. This combination is commonly found in over-the-counter creams such as Optiderm or Balneum Plus for eczema, xerosis (dry skin), atopic dermatitis, psoriasis, ichthyosis, and other pruritic dermatoses[3][4]. **Developers:** Almirall **Manufacturers:** Almirall
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polidocanol + urea.